Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54
Mandate

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54

November 11, 2021 M&A Intellectual Property Commercial Agreements Employment and Benefits

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54 making it one of the first major consolidations of leading e-commerce SaaS solutions in search, merch and personalization.

The merging of their proprietary algorithms will enable FACT-Finder customers to provide digital experiences that are unlike any other on the market and further expand FACT-Finder's international presence.

Vinge’s team consisted of responsible partner Matthias Pannier and associates Vilhelm Rondahl, Gustav Persson, Ebba Nyberg (M&A), Isabell Nielsen, Karl-Gustaw Tobola, Karolina Fuhrmann (Commercial Agreements/IT), Sofia Bergenstråhle (Intellectual Property), Carl Östlund (Employment), Karl-Hugo Engdahl (GDPR) and Ulf Pyk (Real Estate).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025